Molecular imaging developer Sofie Biosciences has inked an agreement to purchase radiopharmaceutical developer Zevacor Pharma (previously IBA Molecular North America).
The deal includes Zevacor's manufacturing and distribution network for PET imaging diagnostic and radiotherapeutic products. Zevacor's network consists of 16 radiopharmacies, 18 cyclotrons, and a New Jersey-based site that produces isotopes for diagnostic, therapeutic, and theranostic purposes, Sofie said.
The purchase is expected to be finalized in the next 60 to 90 days.
